Comparative assessment of <scp>PDE</scp> 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis

Abstract

These results provide new information about the effects of Rolipram on EAE, underline PDE7 inhibition as a new therapeutic target for inflammatory diseases and show the value of TC3.6 to prevent EAE, with possible consequences for new therapeutic tools in MS.